

Changes in Siegfried's Executive Committee

Siegfried announces two changes to its Executive Committee: Irene Wosgien, currently serving as Chief Operating Officer Drug Substances (COO DS), will take over the global responsibility as Chief Human Resources Officer (CHRO) from Arnoud Middel who will leave Siegfried end of June 2023. Henrik Krüpper, currently CEO of HCS Group, will join Siegfried to become the new COO DS.

Irene Wosgien will take over as CHRO on 1 July 2023 while Arnoud Middel will assist her during the transition and will continue to support key HR projects until the end of the year. Henrik Krüpper will assume his role on 1 November 2023 at the latest. Until then and starting on 1 July 2023, Marcel Imwinkelried will lead the DS technical operations organization in parallel to his regular role as Chief Operating Officer Drug Products. Both, Irene Wosgien and Henrik Krüpper, will serve as members of Siegfried's Executive Committee.

Arnoud Middel joined Siegfried in 2011 and since then has successfully built a professional global HR function which has been instrumental to Siegfried's organizational development and strong growth over the years. After 12 years with the company, he decided to leave Siegfried in order to pursue private ventures and prepare the next chapters of his career.

Dr. Wolfgang Wienand, Chief Executive Officer of Siegfried: "Arnoud Middel is an exceptional colleague, a strong leader of our global HR teams and a role model in a broader sense. He has, individually as well as together with his teams, significantly contributed to the successful journey that our company has made over the last decade. While I regret Arnoud's decision to leave, I respect his wish to do so and, on behalf of the Board of Directors and the Executive Committee, thank him for the outstanding job he has done for Siegfried and wish him all the best for the future."

Henrik Krüpper (52, German citizen) holds a diploma (Dipl.-Ing.) in mechanical engineering with a specialization in process engineering from the Technical University (RWTH) Aachen (Germany). After completing his studies, he started his career at Th. Goldschmidt AG as site excellence and production manager followed by positions with increasing operational and managerial responsibilities at Evonik Industries AG (formerly Degussa AG), City Solar AG, Q-Cells SE and Solteature GmbH. In 2012, he joined HCS Group, an international specialty chemicals company based in Germany, as Managing Director and Chief Commercial Officer and was appointed to his current role of Chief Executive Officer of the company in 2019.

Wolfgang Wienand: "With Henrik Krüpper as our new COO DS and Irene Wosgien as our new CHRO we have found two experienced professionals who will quickly onboard in their new roles and hit the ground running. Henrik has displayed effective leadership of large organizations and comes with a strong track record of consistent operational execution. Irene has significantly contributed to the positive development of our DS network over the past years. The combination of her deep understanding of our business and our organization

together with her leadership style make her an excellent fit to the new role. With Irene, Henrik and Christian Dowdeswell, who will start as Chief Business Officer for DS on 6 June 2023, the executive team of Siegfried together with the global Siegfried team is set for growth and will continue to build a global leader in our industry."

Contact

Media:

Peter Stierli
Head Corporate Communications
peter.stierli@siegfried.ch
Tel. +41 62 746 15 51

Financial Analysts:

Dr. Reto Suter
Chief Financial Officer
reto.suter@siegfried.ch
Tel. +41 62 746 11 35

Siegfried Holding AG
Untere Bruehlstrasse 4
CH-4800 Zofingen

This media release on the web

www.siegfried.ch/media-releases

About Siegfried

The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain, France, Malta, the USA and China. In 2022, the company achieved sales of 1.229 billion Swiss francs and employed on 31.12.2022 more than 3'600 people at eleven sites on three continents. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services.